Quick Answer
Transcode Therapeutics, Inc. reported Diluted EPS of $47.14 per share (loss) for fiscal year 2024.
Transcode Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$47.14 | +98.6% |
| 2023 | -$3419.01 | -215.8% |
| 2022 | -$1082.79 | -133577.8% |
| 2021 | -$0.81 | -58.8% |
| 2020 | -$0.51 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.82 | +96.0% | -13.5% |
| June 30, 2025 | -$5.13 | +99.2% | -104.4% |
| March 31, 2025 | -$2.51 | +88.2% | +98.3% |
| September 30, 2024 | -$146.06 | -201.5% | +78.5% |
| June 30, 2024 | -$680.23 | -377.8% | -3086.1% |
| March 31, 2024 | -$21.35 | +91.8% | +55.9% |
| September 30, 2023 | -$48.44 | -632.8% | +66.0% |
| June 30, 2023 | -$142.38 | -1877.5% | +45.0% |
- Transcode Therapeutics, Inc. showed an increase of +98.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, Transcode Therapeutics, Inc.’s diluted eps has declined by 9143.1% (from $0.51 per share (loss) to $47.14 per share (loss)).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: